Truist analyst Richard Newitter lowered the firm’s price target on Zimmer Biomet (ZBH) to $113 from $118 and keeps a Hold rating on the shares.

Stratos Wealth Partners LTD. lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 2.5% during the ...

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report), with a price ...

This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid ...

Zimmer Biomet Holdings, Inc. ZBH posted fourth-quarter 2024 adjusted earnings per share (EPS) of $2.31, beating the Zacks ...

Price Action: ZBH stock is down 3.13% at $104.86 at last check Thursday. Read Next: AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million ...

If an investor was to purchase shares of ZBH stock at the current price level of $112.92/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

Zimmer Biomet posted Q4 adjusted EPS of $2.31, surpassing estimates, with sales of $2.02B, driven by strong knee and hip product growth. The company expects FY25 adjusted EPS of $8.15-$8.35 ...